• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
BYL719

BYL719

Product ID B9700
Cas No. 1217486-61-7
Purity ≥99%, ≥99%ee
Product Unit SizeCostQuantityStock
1 mg $63.00 In stock
5 mg $116.00 In stock
25 mg $173.00 In stock
100 mg $446.00 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

BYL-719 is an ATP-competitive oral PI3K inhibitor selective for the p110α isoform that is activated by a mutant PIK3CA gene in HER2+ breast cancers and gastric cancers. BYL-719 exhibits anticancer chemotherapeutic activity and inhibits proliferation in a variety of cell lines. IGF1 and neuregulin 1 activate mTOR, a downstream target of PI3K that mediates resistance to BYL-719 in some in vitro cancer models. This compound also decreases invasion and epithelial-to-mesenchymal transition (EMT) in cellular and animal models of squamous cell lung cancer.

Product Info

Cas No.

1217486-61-7

Purity

≥99%, ≥99%ee

Formula

C19H22F3N5O2S

Formula Wt.

441.47

Chemical Name

(2S)-1-N-[4-methyl-5-[2-(1,1, 1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1, 3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamide

IUPAC Name

(2S)-1-N-[4-methyl-5-[2-(1,1, 1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1, 3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamide

Synonym

Alpelisib, NVP-BYL719, BYL-719

Solubility

DMSO 88 mg/mL (199.33 mM) Ethanol 2 mg/mL (4.53 mM) Water Insoluble

Appearance

White Crystal Powder

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

B9700 MSDS PDF

Info Sheet

B9700 Info Sheet PDF

References

Bonelli MA, Cavazzoni A, Saccani F, et al. Inhibition of PI3K pathway reduces invasiveness and epithelial-to-mesenchymal transition in squamous lung cancer cell lines harboring PIK3CA gene alterations. Mol Cancer Ther. 2015 May 26. [Epub ahead of print]. PMID: 26013318.

Elkabets M, Vora S, Juric D, et al. mTORC1 Inhibition Is Required for Sensitivity to PI3K p110α Inhibitors in PIK3CA-Mutant Breast Cancer. Sci Transl Med. 2013 Jul 31;5(196):196ra99. PMID: 23903756.

Abstract: Juric. BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study. American Association for Cancer Research. 2012.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • C8501

    CV-66

    1,8-Diaza-anthracene-tetrone; JNK and ERK5 inhi...

    ≥60%
  • D3447

    Diltiazem Hydrochloride

    Benzothiazepine; L-type Ca2+ channel blocker, p...

    ≥98%
  • Y0002

    Y-320

    Phenylpyrazoleanilide; IL-17 production inhibit...

    ≥98%
  • V1871

    Veratridine

    Binds to neurotoxin receptor site 2 on voltage-...

    ≥98%
  • T0092

    1-Hydroxybaccatin I

    Diterpene found in Taxus; potential microtubule...

    ≥96%
  • R2713

    Recombinant HCV-NS4 Antigens

    Recombinant HCV antigen fragment.

    ≥95%
  • I7359

    1-Isothiocyanato-8-(methylsulfenyl)-octane

    ITC, erucin analog.

    ≥98%
  • A4854

    β-Amyloid Peptide (1-42), rat

    Endogenous APP peptide cleavage product, primar...

    ≥95%
  • E4785

    Elvitegravir

    Integrase inhibitor.

    ≥98%
  • C3210

    Ciglitazone

    Thiazolidinedione; PPARγ agonist.

    ≥98%
  • P7059

    Proxymetacaine Hydrochloride

    Potential voltage-gated Na+ channel blocker.

    ≥98%
  • C0167

    Carbenoxolone

    Synthetic glycyrrhetinic acid derivative; 11β-...

    ≥98%
  • P3456

    Pimobendan

    PDE3 inhibitor.

    ≥99%
  • F4683

    Fluticasone Propionate

    β2-adrenergic agonist.

    ≥98%
  • C0044

    CAL101

    p110δ PI3K inhibitor.

    ≥99%
  • B3458

    Biopterin

    Endogenous pterin coenzyme required for release...

    ≥98%
  • P691320

    PRI-724

    Wnt/beta-catenin/CBP inhibitor

    ≥98%
  • O486181

    Omeprazole Related Compound B

    Impurity of omeprazole

    ≥99%
  • L5769

    Lorglumide Sodium

    CCK antagonist.

    ≥98%
  • R5745

    Rolipram

    Anxiolytic-like agent that stimulates angiogene...

    ≥98%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2026 LKT Laboratories, All Rights Reserved - Products for research use only